Observational studyCritical care (London, England)2026
Association between obesity and kidney outcomes in critically ill patients with acute kidney injury receiving continuous renal replacement therapy: a secondary analysis of the multicenter CRRTnet study.
Observational study in Critical care (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02034448 (CRRTNet Outcome Registry), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
CRRTNet Outcome Registry
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundContinuous renal replacement therapy (CRRT) is frequently utilized in critically ill adults with acute kidney injury (AKI). Outcomes among obese patients receiving CRRT, however, are poorly characterized, and the modifying effect of CRRT dose-intensity remains uncertain. This study examined the association between obesity and mortality among critically ill adults receiving CRRT and whether the method used to calculate body weight modified the association between prescribed CRRT dose-intensity and mortality.
methodsWe conducted a secondary analysis of the prospective, multicenter observational CRRTnet study, which enrolled critically ill adults with AKI receiving CRRT. Patients who received < 24 h of CRRT were excluded. Primary outcomes were in-hospital mortality, compared between obese (body mass index [BMI] ≥ 30 kg/m2) and non-obese (BMI < 30 kg/m2) patients, and by prescribed CRRT dose-intensity determined by actual body weight (ABW), ideal body weight (IBW), and adjusted-body weight (Adj-BW).
resultsAmong 890 patients (478 obese and 412 non-obese), median BMI was 36.3 kg/m2 (interquartile range [IQR], 32.9–41.7) for obese and 25.5 kg/m2 (IQR, 23.3–27.8) for non-obese patients (p < 0.001). In-hospital mortality was similar between groups (53.8% vs. 52.4%; p = 0.74). In multivariable analysis, obesity was independently associated with increased mortality (adjusted-odds ratio [adj-OR], 1.53; 95% confidence interval [CI], 1.03–2.28; p = 0.034). Greater prescribed CRRT dose-intensity (per 5 mL/kg/h increase) was associated with greater odds of in-hospital mortality, when indexed to ABW (adj-OR, 1.17; 95% CI, 1.10–1.25; p < 0.001), IBW (adj-OR, 1.13; 95% CI, 1.09–1.18; p < 0.001), and Adj-BW (adj-OR, 1.19; 95% CI, 1.13–1.27; p < 0.001).
conclusionsAmong critically ill adults with AKI receiving CRRT, obesity appears to confer greater risk of in-hospital mortality, and greater prescribed CRRT dose-intensity was consistently associated with greater mortality risk across all weight-based indices. These findings highlight the potential necessity for modifying CRRT prescription practices among obese patients and highlight the need for further research on optimal CRRT dose-intensity prescription across a broad spectrum of critically ill patients.
trial registrationThis study was prospectively registered on ClinicalTrials.gov (NCT02034448) on January 10, 2014.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.